Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY: RMD )

228.48 -0.21 (-0.09%)
Official Closing Price Updated: 4:10 PM EST, Jan 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 557,913
Open 230.99
Bid (Size) 225.00 (1)
Ask (Size) 244.55 (2)
Prev. Close 228.69
Today's Range 226.66 - 230.99
52wk Range 164.12 - 260.49
Shares Outstanding 146,234,244
Dividend Yield 0.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. 
Via Investor's Business Daily
Exposures Product Safety
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga

Performance

YTD
N/A
N/A
1 Month
-6.71%
-6.71%
3 Month
-4.35%
-4.35%
6 Month
+20.63%
+20.63%
1 Year
+33.01%
+33.01%

More News

Read More
Should you consider RESMED INC (NYSE:RMD) for quality investing?
Via Chartmill
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
Via Investor's Business Daily
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Via Chartmill
ResMed Announces Participation in the UBS Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
P/E Ratio Insights for ResMed
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ResMed
Via Benzinga
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
Via Investor's Business Daily
A Peek at ResMed's Future Earnings
Via Benzinga
Is RESMED INC (NYSE:RMD) suited for quality investing?
Via Chartmill
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
Via The Motley Fool
Obesity Drugs-Tied ResMed Edges Higher On Quarterly Beat
Via Investor's Business Daily
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025
From ResMed Inc.
Via GlobeNewswire
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024
From ResMed Inc.
Via GlobeNewswire
Expert Outlook: ResMed Through The Eyes Of 7 Analysts
Via Benzinga
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
From ResMed Inc.
Via GlobeNewswire
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
From ResMed Inc.
Via GlobeNewswire
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
From ResMed Inc.
Via GlobeNewswire
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
From ResMed Inc.
Via GlobeNewswire
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
From ResMed Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 21
Via Talk Markets
Why ResMed Stock Tumbled by 5% Today
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.